Palvella Therapeutics announces new data from the phase 2 Toiva trial of Qtorin(TM) rapamycin in cutaneous venous malformations

Published: 2026-05-15 07:37:26 ET PVLA

Published on 05/15/2026 at 07:37 am EDT